Synthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseases

BioEssays

Volumn 36, Issue 10, 2014, Pages 979-990

  Agustín Pavón, Carmen ^a   Isalan, Mark ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Artificial cell systems; Genome editing; Neurodegeneration; Synthetic proteins

Indexed keywords

MESSENGER RNA; NEUROTROPHIC FACTOR; NUCLEASE; PROTEIN; SYNTHETIC DNA; TRANSCRIPTION FACTOR;

ARTICLE; ARTIFICIAL CELL; BRAIN DEGENERATION; CELL TRANSPLANTATION; CLEARANCE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DEGENERATIVE DISEASE; GENE CONTROL; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENOME; HOST; HUMAN; LONG TERM CARE; MEDICAL TECHNOLOGY; MODIFIER GENE; NEUROPROTECTION; NONHUMAN; RNA INTERFERENCE; SYNTHETIC BIOLOGY; TRANSGENE; ANIMAL; BRAIN; GENETICS; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY;

ANIMALS; BRAIN; CELL TRANSPLANTATION; GENETIC THERAPY; HUMANS; NEURODEGENERATIVE DISEASES; SYNTHETIC BIOLOGY; TRANSCRIPTION FACTORS;

EID: 84908244830     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201400094     Document Type: Article

References (117)

1. Reardon S. 2014. Brain-mapping projects to join forces. Nat News doi: 10.1038/nature.2014.14871
2. Evans SJ, Douglas I, Rawlins MD, Wexler NS, et al. 2013. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry 84: 1156-60.
3. Thies W, Bleiler L, Alzheimer's A. 2013. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 9: 208-45.
4. Byers AL, Yaffe K. 2011. Depression and risk of developing dementia. Nat Rev Neurol 7: 323-31.
5. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, et al. 2011. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21: 655-79.
6. Lu B, Nagappan G, Guan X, Nathan PJ, et al. 2013. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci 14: 401-16.
7. Julien CL, Thompson JC, Wild S, Yardumian P, et al. 2007. Psychiatric disorders in preclinical Huntington's disease. J Neurol Neurosurg Psychiatry 78: 939-43.
8. Weintraub D, Burn DJ. 2011. Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord 26: 1022-31.
9. Menendez-Gonzalez M. 2014. The many questions on the use of biomarkers for neurodegenerative diseases in clinical practice. Front Aging Neurosci 6: 45.
10. Auslander S, Auslander D, Muller M, Wieland M, et al. 2012. Programmable single-cell mammalian biocomputers. Nature 487: 123-7.
11. Moon TS, Lou C, Tamsir A, Stanton BC, et al. 2012. Genetic programs constructed from layered logic gates in single cells. Nature 491: 249-53.
12. Garriga-Canut M, Agustin-Pavon C, Herrmann F, Sanchez A, et al. 2012. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA 109: E3136-45.
13. Xie Z, Wroblewska L, Prochazka L, Weiss R, et al. 2011. Multi-input RNAi-based logic circuit for identification of specific cancer cells. Science 333: 1307-11.
14. Shalem O, Sanjana NE, Hartenian E, Shi X, et al. 2014. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343: 84-7.
15. Miller JC, Tan S, Qiao G, Barlow KA, et al. 2011. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29: 143-8.
16. Urnov FD, Miller JC, Lee YL, Beausejour CM, et al. 2005. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435: 646-51.
17. Gardner TS, Hawkins K. 2013. Synthetic biology: evolution or revolution? A co-founder's perspective. Curr Opin Chem Biol 17: 871-7.
18. Basu S, Gerchman Y, Collins CH, Arnold FH, et al. 2005. A synthetic multicellular system for programmed pattern formation. Nature 434: 1130-4.
19. Carvalho A, Menendez DB, Senthivel VR, Zimmermann T, et al. 2014. Genetically encoded sender-receiver system in 3D mammalian cell culture. ACS Synth Biol 3: 264-72.
20. Ro DK, Paradise EM, Ouellet M, Fisher KJ, et al. 2006. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440: 940-3.
21. Regot S, Macia J, Conde N, Furukawa K, et al. 2011. Distributed biological computation with multicellular engineered networks. Nature 469: 207-11.
22. Nawroth JC, Lee H, Feinberg AW, Ripplinger CM, et al. 2012. A tissue-engineered jellyfish with biomimetic propulsion. Nat Biotechnol 30: 792-7.
23. Yu D, Pendergraff H, Liu J, Kordasiewicz HB, et al. 2012. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150: 895-908.
24. Bartus RT, Baumann TL, Siffert J, Herzog CD, et al. 2013. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80: 1698-701.
25. Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, et al. 2014. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383: 1138-46.
26. Biffi A, Montini E, Lorioli L, Cesani M, et al. 2013. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341: 1233158.
27. Ross CA, Tabrizi SJ. 2011. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10: 83-98.
28. Fjord-Larsen L, Kusk P, Emerich DF, Thanos C, et al. 2012. Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer. Gene Ther 19: 1010-7.
29. Wahlberg LU, Lind G, Almqvist PM, Kusk P, et al. 2012. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J Neurosurg 117: 340-7.
30. Stolberg SG. 1999. The biotech death of Jesse Gelsinger. NY Times Mag 136-40: 49-50.
31. Basner-Tschakarjan E, Bijjiga E, Martino AT. 2014. Pre-clinical assessment of immune responses to adeno-associated virus (AAV) vectors. Front Immunol 5: 28.
32. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, et al. 2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-50.
33. Papayannakos C, Daniel R. 2013. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy. Gene Ther 20: 581-8.
34. Ciesielska A, Hadaczek P, Mittermeyer G, Zhou S, et al. 2013. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther 21: 158-66.
35. Hadaczek P, Forsayeth J, Mirek H, Munson K, et al. 2009. Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther 20: 225-37.
36. Samaranch L, San Sebastian W, Kells AP, Salegio EA, et al. 2014. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther 22: 329-37.
37. Parker AS, Zheng W, Griswold KE, Bailey-Kellogg C. 2010. Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinformatics 11: 180.
38. Perez-Pinera P, Ousterout DG, Brunger JM, Farin AM, et al. 2013. Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat Methods 10: 239-42.
39. Gilbert LA, Larson MH, Morsut L, Liu Z, et al. 2013. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154: 442-51.
40. Maeder ML, Linder SJ, Cascio VM, Fu Y, et al. 2013. CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10: 977-9.
41. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, et al. 2012. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74: 1031-44.
42. Singh NK, Singh NN, Androphy EJ, Singh RN. 2006. Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26: 1333-46.
43. Hua Y, Vickers TA, Okunola HL, Bennett CF. et al. 2008. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82: 834-48.
44. Williams JH, Schray RC, Patterson CA, Ayitey SO. et al. 2009. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci 29: 7633-8.
45. Zanetta C, Nizzardo M, Simone C, Monguzzi E, et al. 2014. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. Clin Ther 36: 128-40.
46. Vucicevic D, Schrewe H, Orom UA. 2014. Molecular mechanisms of long ncRNAs in neurological disorders. Front Genet 5: 48.
47. Riboldi G, Zanetta C, Ranieri M, Nizzardo M, et al. 2014. Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases. Mol Neurobiol in press, doi: 10.1007/s12035-014-8724-7
48. Martin JN, Wolken N, Brown T, Dauer WT, et al. 2011. Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. Gene Ther 18: 666-73.
49. Khodr CE, Sapru MK, Pedapati J, Han Y, et al. 2011. An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res 1395: 94-107.
50. Ehlert EM, Eggers R, Niclou SP, Verhaagen J. 2010. Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neurosci 11: 20.
51. McBride JL, Boudreau RL, Harper SQ, Staber PD, et al. 2008. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868-73.
52. Pinheiro VB, Taylor AI, Cozens C, Abramov M, et al. 2012. Synthetic genetic polymers capable of heredity and evolution. Science 336: 341-4.
53. Morbitzer R, Romer P, Boch J, Lahaye T. 2010. Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-type transcription factors. Proc Natl Acad Sci USA 107: 21617-22.
54. Hu J, Lei Y, Wong WK, Liu S, et al. 2014. Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors. Nucleic Acids Res 42: 4375-90.
55. Mussolino C, Sanges D, Marrocco E, Bonetti C, et al. 2011. Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. EMBO Mol Med 3: 118-28.
56. Kliem MA, Heeke BL, Franz CK, Radovitskiy I, et al. 2011. Intramuscular administration of a VEGF zinc finger transcription factor activator (VEGF-ZFP-TF) improves functional outcomes in SOD1 rats. Amyotroph Lateral Scler 12: 331-9.
57. Rebar EJ, Huang Y, Hickey R, Nath AK, et al. 2002. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med 8: 1427-32.
58. Laganiere J, Kells AP, Lai JT, Guschin D, et al. 2010. An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease. J Neurosci 30: 16469-74.
59. Ellison SM, Trabalza A, Tisato V, Pazarentzos E, et al. 2013. Dose-dependent neuroprotection of VEGF(1)(6)(5) in Huntington's disease striatum. Mol Ther 21: 1862-75.
60. Christian M, Cermak T, Doyle EL, Schmidt C, et al. 2010. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186: 757-61.
61. Mali P, Yang L, Esvelt KM, Aach J, et al. 2013. RNA-guided human genome engineering via Cas9. Science 339: 823-6.
62. Li M, Suzuki K, Kim NY, Liu GH, et al. 2014. A cut above the rest: targeted genome editing technologies in human pluripotent stem cells. J Biol Chem 289: 4594-9.
63. Tebas P, Stein D, Tang WW, Frank I, et al. 2014. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370: 901-10.
64. Fu Y, Foden JA, Khayter C, Maeder ML, et al. 2013. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31: 822-6.
65. Wang J, Friedman G, Doyon Y, Wang NS, et al. 2012. Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme. Genome Res 22: 1316-26.
66. Ran FA, Hsu PD, Lin CY, Gootenberg JS, et al. 2013. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154: 1380-9.
67. Hsu PD, Scott DA, Weinstein JA, Ran FA, et al. 2013. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31: 827-32.
68. Konermann S, Brigham MD, Trevino AE, Hsu PD, et al. 2013. Optical control of mammalian endogenous transcription and epigenetic states. Nature 500: 472-6.
69. Guo JL, Lee VM. 2014. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 20: 130-8.
70. Yanamandra K, Kfoury N, Jiang H, Mahan TE, et al. 2013. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80: 402-14.
71. Panza F, Logroscino G, Imbimbo BP, Solfrizzi V. 2014. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? Curr Opin Psychiatry 27: 128-37.
72. Adams JJ, Sidhu SS. 2014. Synthetic antibody technologies. Curr Opin Struct Biol 24C: 1-9.
73. de Chiara C, Pastore A. 2014. Kaleidoscopic protein-protein interactions in the life and death of ataxin-1: new strategies against protein aggregation. Trends Neurosci 37: 211-8.
74. Bauer PO, Goswami A, Wong HK, Okuno M, et al. 2010. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotechnol 28: 256-63.
75. Garg S, Oran AE, Hon H, Jacob J. 2004. The hybrid cytomegalovirus enhancer/chicken beta-actin promoter along with woodchuck hepatitis virus posttranscriptional regulatory element enhances the protective efficacy of DNA vaccines. J Immunol 173: 550-8.
76. Delzor A, Dufour N, Petit F, Guillermier M, et al. 2012. Restricted transgene expression in the brain with cell-type specific neuronal promoters. Hum Gene Ther Meth 23: 242-54.
77. Portales-Casamar E, Swanson DJ, Liu L, de Leeuw CN, et al. 2010. A regulatory toolbox of MiniPromoters to drive selective expression in the brain. Proc Natl Acad Sci USA 107: 16589-94.
78. Kelly JR, Rubin AJ, Davis JH, Ajo-Franklin CM, et al. 2009. Measuring the activity of BioBrick promoters using an in vivo reference standard. J Biol Eng 3: 4.
79. Trinklein ND, Aldred SJ, Saldanha AJ, Myers RM. 2003. Identification and functional analysis of human transcriptional promoters. Genome Res 13: 308-12.
80. Katznelson L, Loriaux DL, Feldman D, Braunstein GD, et al. 2014. Global clinical response in Cushing's syndrome patients treated with mifepristone. Clin Endocrinol (Oxf) 80: 562-9.
81. Maddalena A, Tereshchenko J, Bahr M, Kugler S. 2013. Adeno-associated virus-mediated, mifepristone-regulated transgene expression in the brain. Mol Ther Nucleic Acids 2: e106.
82. Ye H, Charpin-El Hamri G, Zwicky K, Christen M, et al. 2013. Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. Proc Natl Acad Sci USA 110: 141-6.
83. Packer AM, Roska B, Hausser M. 2013. Targeting neurons and photons for optogenetics. Nat Neurosci 16: 805-15.
84. Polstein LR, Gersbach CA. 2012. Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors. J Am Chem Soc 134: 16480-3.
85. Katzenschlager R. 2014. Parkinson's disease: recent advances. J Neurol 261: 1031-6.
86. Wykes RC, Heeroma JH, Mantoan L, Zheng K, et al. 2012. Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci Transl Med 4: 161ra52.
87. Greber D, Fussenegger M. 2010. An engineered mammalian band-pass network. Nucleic Acids Res 38: e174.
88. Nissim L, Bar-Ziv RH. 2010. A tunable dual-promoter integrator for targeting of cancer cells. Mol Syst Biol 6: 444.
89. Rossger K, Charpin-El Hamri G, Fussenegger M. 2013. Reward-based hypertension control by a synthetic brain-dopamine interface. Proc Natl Acad Sci USA 110: 18150-5.
90. Emerich DF, Orive G, Thanos C, Tornoe J, et al. 2013. Encapsulated cell therapy for neurodegenerative diseases: from promise to product. Adv Drug Deliv Rev 67-68: 131-41.
91. Salamone JD, Correa M. 2012. The mysterious motivational functions of mesolimbic dopamine. Neuron 76: 470-85.
92. Tigges M, Marquez-Lago TT, Stelling J, Fussenegger M. 2009. A tunable synthetic mammalian oscillator. Nature 457: 309-12.
93. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, et al. 2014. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20: 415-8.
94. Tong X, Ao Y, Faas GC, Nwaobi SE, et al. 2014. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat Neurosci 17: 694-703.
95. Nerrant E, Charif M, Ayrignac X, Carra-Dalliere C, et al. 2014. Is KIR4.1 antibody a marker of multiple sclerosis? Neurology 82: Supplement P4.130.
96. Gil B, Kahan-Hanum M, Skirtenko N, Adar R, et al. 2011. Detection of multiple disease indicators by an autonomous biomolecular computer. Nano Lett 11: 2989-96.
97. Hamilton LK, Joppe SE, Cochard LM, Fernandes KJ. 2013. Aging and neurogenesis in the adult forebrain: what we have learned and where we should go from here. Eur J Neurosci 37: 1978-86.
98. Ernst A, Alkass K, Bernard S, Salehpour M, et al. 2014. Neurogenesis in the striatum of the adult human brain. Cell 156: 1072-83.
99. Stockwell J, Abdi N, Lu X, Maheshwari O, et al. 2014. Novel central nervous system drug delivery systems. Chem Biol Drug Des 83: 507-20.
100. Mulcahy PJ, Iremonger K, Karyka E, Herranz-Martin S, et al. 2014. Gene therapy: a promising approach to treating SMA. Hum Gene Ther 25: 575-86.
101. Soldner F, Laganiere J, Cheng AW, Hockemeyer D, et al. 2011. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146: 318-31.
102. Fong H, Wang C, Knoferle J, Walker D, et al. 2013. Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Rep 1: 226-34.
103. Marchetto MC, Gage FH. 2012. Modeling brain disease in a dish: really? Cell Stem Cell 10: 642-5.
104. Zhou J, Shen B, Zhang W, Wang J, et al. 2014. One-step generation of different immunodeficient mice with multiple gene modifications by CRISPR/Cas9 mediated genome engineering. Int J Biochem Cell Biol 46: 49-55.
105. Hwang WY, Fu Y, Reyon D, Maeder ML, et al. 2013. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 31: 227-9.
106. Niu Y, Shen B, Cui Y, Chen Y, et al. 2014. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156: 836-43.
107. Liu H, Chen Y, Niu Y, Zhang K, et al. 2014. TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys. Cell Stem Cell 14: 323-8.
108. Agustin-Pavon C, Braesicke K, Shiba Y, Santangelo AM, et al. 2012. Lesions of ventrolateral prefrontal or anterior orbitofrontal cortex in primates heighten negative emotion. Biol Psychiatry 72: 266-72.
109. Kishi N, Sato K, Sasaki E, Okano H. 2014. Common marmoset as a new model animal for neuroscience research and genome editing technology. Dev Growth Differ 56: 53-62.
110. Adolfsson O, Pihlgren M, Toni N, Varisco Y, et al. 2012. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 32: 9677-89.
111. Gross RE, Watts RL, Hauser RA, Bakay RA, et al. 2011. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 10: 509-19.
112. Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, et al. 2012. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 23: 377-81.
113. Kefalopoulou Z, Politis M, Piccini P, Mencacci N, et al. 2014. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 71: 83-7.
114. Herrmann F, Garriga-Canut M, Baumstark R, Fajardo-Sanchez E, et al. 2011. p53 Gene repair with zinc finger nucleases optimised by yeast 1-hybrid and validated by Solexa sequencing. PLoS One 6: e20913.
115. Bibikova M, Carroll D, Segal DJ, Trautman JK, et al. 2001. Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol Cell Biol 21: 289-97.
116. Li T, Huang S, Jiang WZ, Wright D, et al. 2011. TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res 39: 359-72.
117. Cong L, Ran FA, Cox D, Lin S, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-23.